CLINICAL EFFECTIVENESS AND TOLERABILITY OF VANCOMYCIN-BELPHARM IN THE TREATMENT OF SURGICAL SOFT TISSUE INFECTIONS

Abstract

A randomized comparative study of the clinical effectiveness and tolerability of the locally produced drug «Vancomycin-Belpharm» (produced by IP LLC "BELPHARM", Uzbekistan) in comparison with the reference drug «Vancomycin» (LLC "Farmkontsept", Russia) in the treatment of surgical soft tissue infections (SSTI) was conducted. Effectiveness was evaluated based on a three — point scale (clinical symptoms, pathogen eradication, dynamics of laboratory parameters), tolerability-on a four-point scale (objective and subjective signs of adverse reactions). The results showed a comparable high clinical efficacy of both drugs: a significant decrease in body temperature (up to 36.8°C), a marked reduction in pain and signs of local inflammation, and cleaning of the wound process (from 3.0 to 1.13–1.25 points). The average efficiency score was 2.9±0.54 in the main group and 2.70±0.92 in the control group. Tolerance was also high and comparable: 3.9±0.7 and 3.73±1.01 points, respectively. Cases of intolerance (chills, hyperthermia that required withdrawal) were rare in two patients of the main group and in one patient of the control group.  Vancomycin-Belpharm demonstrated clinical effectiveness, safety, and tolerability fully comparable to the original (reference) drug. The drug can be recommended for inclusion in standard chemo therapy regimens, which is especially important in the context of import substitution, increasing the availability of treatment and supporting local production in the Republic of Uzbekistan.